Cytosine Arabinoside and Mitoxantrone Followed by Second Allogeneic Transplant for the Treatment of Children With Refractory Juvenile Myelomonocytic Leukemia

Autor: Peter F. Coccia, Phyllis I. Warkentin, Warren G. Sanger, James L. Wisecarver, Sachit Patel, James Harper, Bruce Geoffrey Gordon, Don W. Coulter, Alfred C. Grovas
Rok vydání: 2014
Předmět:
Male
Antimetabolites
Antineoplastic

medicine.medical_specialty
Transplantation Conditioning
medicine.medical_treatment
Hematopoietic stem cell transplantation
Philadelphia chromosome
Gastroenterology
Disease-Free Survival
Monocytosis
Recurrence
Internal medicine
medicine
Humans
Transplantation
Homologous

Leukocytosis
Child
JMML
Transplantation Chimera
Juvenile myelomonocytic leukemia
business.industry
Cytarabine
Hematopoietic Stem Cell Transplantation
Infant
Original Articles
Hematology
allogeneic transplant
medicine.disease
Combined Modality Therapy
Tissue Donors
PTPN11
surgical procedures
operative

chimerism
Leukemia
Myelomonocytic
Juvenile

Oncology
Child
Preschool

Retreatment
Pediatrics
Perinatology and Child Health

Immunology
Noonan syndrome
Mitoxantrone
medicine.symptom
business
medicine.drug
Zdroj: Journal of Pediatric Hematology/Oncology
ISSN: 1077-4114
DOI: 10.1097/mph.0000000000000077
Popis: Juvenile myelomonocytic leukemia (JMML) is a rare mixed myelodysplastic and myeloproliferative clonal disorder of early childhood representing about 1% to 2% of all pediatric leukemias.1–3 Most cases present before 6 years of age, with a median age of 2 years. Clinical presentation includes pallor, rash, hepatomegaly, splenomegaly, lymphadenopathy, and recurrent infections.2–5 JMML has an increased incidence in patients with neurofibromatosis and Noonan syndrome as well as genetic mutations in the RAS signaling pathway, PTPN11, CBL, and NF1 gene.6–10 Although most children demonstrate a normal karyotype, monosomy 7 and other chromosome 7 abnormalities are reported in 25% of cases.4 Diagnostic criteria as defined by the International JMML Working Group include peripheral blood monocytosis >1000/mm3, absence of the Philadelphia chromosome t(9:22) and the BCR-ABL1 fusion gene rearrangement, and bone marrow blasts
Databáze: OpenAIRE